Hengrui Medicine: Subsidiary HRS-7535 tablets approved for clinical trials of drugs.

Hengrui Pharmaceuticals announced that its subsidiary Shandong Shengdi Pharmaceuticals has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for HRS-7535 tablets, and will start clinical trials in the near future. This drug is intended for the treatment of hypertension combined with overweight or obesity, and is a new type of oral small molecule glucagon-like peptide-1 receptor agonist, with no similar oral drugs on the market globally. As of now, the total research and development investment for the related project is approximately 369 million yuan. The process from drug development to market launch is long and involves many stages, with uncertainties. The company will continue to move forward with the project and disclose progress.